Clinical trials of tamoxifen - TrialResults-center.org

Soltamox - ICI46474 - ICI 46474 - ICI-46474 - Zitazonium - Tomaxithen - Tamoxifen Citrate - Novaldex - Nolvadex - ICI47699 - ICI 47699 - ICI-47699 - Tamoxifen

pathology

Benefit (demonstrated or suggested) and harm

advanced breast cancer (metastatic)

All results are NS for efficacy

meta-analysis

Trial	control	p<0.05	harm	NS
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment
	vs no systemic treatment

Trial	Treatments	Patients	Method
Beelen, 2014	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
Beex, 2006	(n=-9) vs. (n=-9)	first line endocrine treatment in advanced breast	Sample size: -9/-9 Primary endpoint: FU duration:
Sawka, 1997	(n=-9) vs. (n=-9)	metastatic breast cancer in premenopausal women	Sample size: -9/-9 Primary endpoint: FU duration:
Kuss, 1997	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
Stuart, 1996	(n=-9) vs. (n=-9)	advanced and recurrent breast cancer	Sample size: -9/-9 Primary endpoint: FU duration:
Willsher, 1996	(n=-9) vs. (n=-9)	Locally advanced breast cancer	Sample size: -9/-9 Primary endpoint: FU duration:
Muss, 1994	(n=-9) vs. (n=-9)	patients with metastatic breast cancer	Sample size: -9/-9 Primary endpoint: FU duration:
Gill, 1993	(n=-9) vs. (n=-9)	patients with metastatic breast cancer	Sample size: -9/-9 Primary endpoint: FU duration:
Castiglione-Gertsch, 1993	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
Spooner, 1991	(n=-9) vs. (n=-9)	advanced breast cancer	Sample size: -9/-9 Primary endpoint: FU duration:
De Lena, 1990	(n=-9) vs. (n=-9)	advanced breast cancer	Sample size: -9/-9 Primary endpoint: FU duration:
Takatsuka, 1989	(n=-9) vs. (n=-9)	advanced breast cancer	Sample size: -9/-9 Primary endpoint: FU duration:
Kellokumpu-Lehtinen, 1987	(n=-9) vs. (n=-9)	advanced breast cancer	Sample size: -9/-9 Primary endpoint: FU duration:
Ettinger, 1986	(n=-9) vs. (n=-9)	advanced breast cancer	Sample size: -9/-9 Primary endpoint: FU duration:
Gockerman, 1986	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
Buchanan, 1986	(n=-9) vs. (n=-9)	premenopausal patients with advanced breast cancer	Sample size: -9/-9 Primary endpoint: FU duration:
van, 1986	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
Ingle, 1986	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
Mauriac, 1986	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
Viladiu, 1985	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
Mouridsen, 1985	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
Perry, 1985	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
Boccardo, 1985	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
Mouridsen, 1985	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
Viladiu, 1985	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
ANZBC, 1986	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
CLKGB 8081 (Perry), 1987	(n=-9) vs. (n=-9)		Sample size: -9/-9 Primary endpoint: FU duration:
ECOG E3186 (Sledge), 2000	chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil CAF) (n=-9) vs. chemohormonal therapy (CAF plus tamoxifen and fluoxymesterone) (n=-9)	patients with estrogen receptor (ER)-positive or ER-unknown metastatic breast cancer	Sample size: -9/-9 Primary endpoint: FU duration:

Tamoxifen selective estrogen receptor modulator (SERM) Description Results

Group by...

Tamoxifen selective estrogen receptor modulator (SERM)
Description Results